| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-126-9-199705010-00003 |
| P698 | PubMed publication ID | 9139554 |
| P50 | author | Jack Sobel | Q92689759 |
| P2093 | author name string | Schuman P | |
| Thompson MA | |||
| Vazquez J | |||
| Peng G | |||
| Goldman AI | |||
| Kerkering T | |||
| el-Sadr W | |||
| Alston B | |||
| Capps L | |||
| Vaughn A | |||
| Besch CL | |||
| Cobb MN | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV/AIDS | Q12199 |
| placebo | Q269829 | ||
| candidiasis | Q273510 | ||
| fluconazole | Q411478 | ||
| prevention of HIV/AIDS | Q7242372 | ||
| P304 | page(s) | 689-696 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. | |
| P478 | volume | 126 |
| Q73605437 | 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) |
| Q35614631 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
| Q44616568 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
| Q50632987 | A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. |
| Q33874835 | Agents for treatment of invasive fungal infections |
| Q24550731 | Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans |
| Q83839447 | Candidiasis (oropharyngeal) |
| Q94017590 | Candidiasis (oropharyngeal) |
| Q34164044 | Candidiasis (oropharyngeal). |
| Q59317427 | Candidiasis and other fungal diseases of the mouth |
| Q33945706 | Clinical management of selected oral fungal and viral infections during HIV-disease. |
| Q33584119 | Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. |
| Q30584803 | Cross-study hierarchical modeling of stratified clinical trial data |
| Q24550733 | Current and emerging azole antifungal agents |
| Q43723795 | Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis |
| Q34490092 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? |
| Q34720549 | Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications |
| Q34775235 | Fungal infections associated with HIV infection |
| Q35177631 | Gender differences and sex-specific manifestations associated with human immunodeficiency virus infection in women |
| Q34056471 | HIV disease: mucocutaneous fungal infections in HIV disease |
| Q93501240 | HIV: prevention of opportunistic infections |
| Q24234875 | Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection |
| Q24236693 | Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children |
| Q24244997 | Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children |
| Q34280580 | Management of Candida species infections in critically ill patients |
| Q36767149 | Management of oral lesions in HIV-positive patients. |
| Q34197248 | Management of patients with recurrent vulvovaginal candidiasis |
| Q35646072 | Management of vulvar pain |
| Q35782813 | Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment |
| Q35038446 | Mucosal candidiasis |
| Q34633796 | Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection |
| Q40827662 | Options for the management of mucosal candidiasis in patients with AIDS and HIV infection |
| Q34632651 | Oral candidal infections and antimycotics |
| Q24680431 | Oral candidiasis |
| Q37371876 | Oral mucosal fungal infections. |
| Q34303424 | Oropharyngeal Candida colonization in human immunodeficiency virus infected patients |
| Q57688843 | Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people |
| Q34122368 | Prophylaxis of opportunistic infections. |
| Q33726292 | The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents |
| Q34085884 | Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. |
| Q36767158 | Use of prophylactic antifungals in the immunocompromised host. |
| Q34636211 | Vulvovaginal candidosis |
| Q33543369 | Vulvovaginitis due to Candida glabrata. An emerging problem |
Search more.